About

DeepLife is a biotech company with a mission to cure disease one cell at a time with Digital Twins of cells.

We develop novel approaches based on state-of the art multi-omics data, AI and systems engineering to identify molecular triggers driving diseased cells back in their healthy state.

Our team’s DNA is encoded with 4 letters:

Ambitious

Creative

Talented

Goal-Oriented People

View Available Careers

About

Product

OmicStore Cell Blueprint

Pipeline News & Media Events Contact

PRESS KIT

Pioneering AI-driven drug development

Media contact

DeepLife experts are available to comment on topics related to AI, drug repurposing and digital twin technology.

pr@deeplife.co

DeepLife Graphic Assets

Company boilerplate

DeepLife is a techbio company advancing drug positioning through artificial intelligence and digital twins of human cell types. Its platform maps cell-type–specific regulatory networks by integrating over 100 million harmonized single-cell omics data points, enabling more precise target identification and disease understanding.

FAQ

What is DeepLife’s mission?

DeepLife’s mission is to revolutionize cure disease through digital twins of cell technology, leveraging multiomics data, AI and systems engineering to identify molecular triggers that restore diseased cells to a healthy state.

What is DeepLife’s founding story?

DeepLife was founded in 2019 by Jonathan Baptista (CEO) and Jean-Baptiste Morlot (CTO) to tackle the inefficiencies of traditional drug development through AI combined with multi-omics data. The co-founders combined their expertise in complex systems simulation and machine learning applied to genetics to pioneer AI-driven digital twins of cells - virtual models that simulate cellular behaviour.

Is DeepLife a platform biotech or a drug development company?

DeepLife is a techbio company developing a platform that integrates digital twin cell modeling, multi-omics data and AI to de-risk and accelerate drug development by simulating cellular responses, identifying therapeutic targets and repositioning drugs with existing safety profiles.

How much investment has DeepLife received?

DeepLife has raised a total of $16M in funding so far. They recently closed a $10M Series A round at the end of 2024, led by YZR Capital and the VC arm of French insurer Relyens, with participation by Beiersdorf Venture Capital and Prunay Group to expand their SaaS platform Cell Blueprint, focusing on solutions for autoimmune and neurodegenerative diseases.

Where is DeepLife based?

DeepLife is a fully remote organization, balancing flexibility with strategic in-person interactions to optimize productivity and innovation through global talent access.

When was DeepLife established?

DeepLife was established in 2019, when co-founders Jonathan Baptista (CEO) and Jean-Baptiste Morlot (CTO) launched the company with a mission to decode cell biology using multi-omics data and AI.

How many employees work at DeepLife?

20 employees currently work at DeepLife, spanning 15+ nationalities across North America and Europe.

Stay tuned to find out more!

Pioneering AI-driven drug development

Media contact

DeepLife Graphic Assets

LinkedIn

Company boilerplate

FAQ